RxDoctor Payments DataLook up a doctor →

Haitham Dib, MD

Cardiovascular Disease · Galloway, NJNPI 1225124613

Payments from drug & device makers

$173,036in general payments, 2019–2025

Across 874 payments — averaging $197.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$65K
  • Boehringer Ingelheim International GmbH$55K
  • Johnson & Johnson$17K
  • Novartis$15K
  • E.r. Squibb & Sons, L.L.C.$7K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • plus $12K from 43 others

What the payments were for

  • Speaking & faculty fees$35,70069%
  • Travel & lodging$1,3963%
  • Food & beverage$14,39928%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,036 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$508,977
Medicare patients
1,026
Services billed
4,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$117,952
FarxigaDapagliflozin Propanediol86$105,944
EliquisApixaban79$104,855
EntrestoSacubitril/Valsartan110$93,166
XareltoRivaroxaban31$35,004
MultaqDronedarone Hcl18$33,296
Ambrisentan11$31,350
Ranolazine ErRanolazine39$4,876
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine17$4,868
Metoprolol Succinate283$4,446
Hydralazine Hcl143$3,498
Nebivolol Hcl44$3,245
Atorvastatin Calcium159$2,073
Valsartan41$1,811
Metoprolol Tartrate109$1,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$660$117,95296 claims
AstraZenecaFarxiga$2,119$105,94486 claims
PfizerEliquis$977$104,85579 claims
NovartisEntresto$15,183$93,166110 claims
Johnson & JohnsonXarelto$16,837$35,00431 claims
Sanofi-aventis U.S. LLCMultaq$95$33,29618 claims
ANI Pharmaceuticals, Inc.Valsartan$20$1,81141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Galloway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →